Searching for treatments for non-G12C-KRAS mutant cancers
Searching for treatments for non-G12C-KRAS mutant cancers
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Summary
KRAS
mutations drive a wide variety of cancers. Drugs targeting the protein product of
KRAS
G12C
mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF–MEK inhibitor, has reported early single agent activity in non-G12C mutated
KRAS
driven cancers.
Alternative Titles
Full title
Searching for treatments for non-G12C-KRAS mutant cancers
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8405631
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8405631
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/s41416-021-01357-2
